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Abstract: Polymeric nanoparticles (NPs) are strong candidates
for the development of systemic and targeted drug delivery appli-
cations. Their size is a determinant property since it deﬁnes the
NP–cell interactions, drug loading capacity, and release kinetics.
Herein, poly(D,L-lactic acid) (PDLA) NPs were produced by the
nanoprecipitationmethod, inwhich the inﬂuence of type and con-
centration of surfactant as well as PDLA concentration were
assessed. The adjustment of these parameters allowed the suc-
cessful production of NPs with deﬁned medium sizes, ranging
from 80 to 460 nm. The surface charge of the different NPs popu-
lations was consistently negative. Prednisolone was effectively
entrapped and released from NPs with statistically different
medium sizes (i.e., 80 or 120 nm). Release proﬁles indicate that
these systems were able to deliver appropriate amounts of drug
with potential applicability in the treatment of inﬂammatory con-
ditions. Both NPs populations were cytocompatible with human
endothelial and ﬁbroblastic cells, in the range of concentrations
tested (0.187–0.784 mg/mL). However, confocal microscopy
revealed that within the range of sizes tested in our experiments,
NPs presenting amedium size of 120 nmwere able to be internal-
ized in endothelial cells. In summary, this study demonstrates the
optimization of the processing conditions to obtain PDLA NPs
with narrow size ranges, and with promising performance for the
treatment of inﬂammatory diseases. © 2018 Wiley Periodicals, Inc. J
BiomedMater Res Part A: 00A: 000–000, 2018.
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INTRODUCTION
Biomaterials structuring at a micro- and nano-scale are sub-
ject of considerable research due to their potential to improve
the safety and efﬁcacy of currently available therapies. Indeed,
the use of these structured biomaterials as delivery devices
allows surpassing solubility problems of the therapeutic
agents, leading to reduced systemic toxicity and tissue dam-
age.1 Additionally, they can be designed to protect drugs, pep-
tides, proteins and nucleic acids from premature degradation
and undesirable interactions with the biological environment,
preserving its bioavailability for longer periods of time.2–5 The
undesirable side effects in surrounding healthy tissues, due to
drug distribution throughout the entire organism, can also be
circumvented by delivering therapeutic agents into a speciﬁc
organ or tissue, using antibodies, peptides or other targeting
moieties linked to the surface of the delivery devices.6–9
Nanoparticles (NPs; 1–1000 nm) have speciﬁc advan-
tages with respect to microparticles (MPs; 1–1000 μm),
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particularly when they need to target deﬁned cells/tissues,
after systemic administration.10 Due to their size, NPs have a
higher speciﬁc surface area than MPs,11 which allows a fas-
ter drug release,12,13 speciﬁcally when diffusion is the main
release mechanism. Moreover, NPs are internalized by cells
15–250 times more than MPs in the 1–10 μm range,14 which
is an essential parameter when an intracellular action is
required. Among all types of NPs,15–19 polymeric ones fulﬁll
a wide range of requirements to be used as delivery devices
of therapeutic agents: (i) their size can be tailored to achieve
speciﬁc biologic actions; (ii) they allow the stabilization of
labile compounds; (iii) the release of loaded drugs can be
controlled by ﬁne-tuning the polymer characteristics;
(iv) they can present a high stability, and (v) their surface
can be easily modiﬁed.20,21 Polymers of different origins
have been proposed to produce NPs for drug delivery, rang-
ing from natural-origin such as chitosan,22,23 alginate,24 gela-
tin, or albumin,25,26 to synthetic-origin like poly(lactic acid)
(PLA), poly(glycolic acid) (PGA) or poly(lactide-co-glycolide)
(PLGA). These synthetic polymers are biodegradable
aliphatic polyesters and, due to their non-toxicity and bio-
compatibility, have been already proposed for medical
applications.27–29 Between the previously referred biode-
gradable aliphatic polyesters, PLA, and more precisely PDLA,
was chosen to be used in this work due to its slow degrada-
tion rate,30 which can be advantageous if a sustained drug
release is desired.
In this work, prednisolone was used as a drug model to
be encapsulated inside PDLA NPs, since this bioactive com-
pound is a broadly used glucocorticoid in the treatment of a
wide range of inﬂammatory conditions.31 However, its con-
ventional administration leads to several adverse effects,
such as osteoporosis, myopathy, and glaucoma.32,33 There-
fore, the incorporation of this glucocorticoid into a delivery
device will allow improving its pharmacokinetic and phar-
macodynamic, and, consequently, increase its therapeutic
index and patient compliance.
Nanoparticles are potential tools to intracellularly deliver
therapeutic agents, such as antiretroviral microbicides 34
and antituberculosis drugs,35 in different cell types.36,37
Therefore, to assess the potential of the developed NPs as
intracellular drug delivery devices without speciﬁc surface
functionalization (e.g., with antibodies to increase the inter-
nalization rate),38–40 both endothelial and ﬁbroblastic cells
were used, to envisage different possible interactions of the
NPs with speciﬁc tissues. Endothelial cells are, for example,
key targets in vascular inﬂammation and, consequently,
in vascular diseases, such as atherosclerosis,41 whereas
ﬁbroblastic cells can be strategic therapeutic targets to
treat chronic inﬂammatory conditions (e.g., rheumatoid
arthritis).42
The main rationale of this work was to produce PDLA
NPs with a conﬁned size range, an efﬁcient drug release pro-
ﬁle and cell internalization ability to treat inﬂammatory dis-
eases. Therefore, PDLA NPs were prepared by an
optimization of the nanoprecipitation method, using different
quantities of surfactant or organic/aqueous (org/aq) volume
ratios. Size distribution and surface electrical charge were
assessed, as well as morphology and storage stability of the
developed PDLA NPs. Loading and entrapment efﬁciencies of
prednisolone and its in vitro release proﬁle were also evalu-
ated. Cytocompatibility studies were performed with human
endothelial and ﬁbroblastic cells by assessing their viability,
proliferation, and total protein content, as well as cell inter-
nalization of PDLA NPs (Scheme 1).
MATERIALS AND METHODS
Reagents
Chemical reagents, unless otherwise noted, were purchased
from Sigma-Aldrich. Poly(D,L-lactic acid) (PDLA 02, MW
17 kg/mol) was kindly provided by Purasorb. Acetone (min.
99.8%) was purchased from Analar Normapur and acetoni-
trile (HPLC grade) was purchased from Fisher Scientiﬁc.
Dubbelco’s modiﬁed eagle’s medium (DMEM), low glucose
DMEM without phenol red and M199 medium were pur-
chased to Sigma-Aldrich. Fetal bovine serum (FBS), Gluta-
max, antibiotic/antimycotic solution (10,000 units/mL
penicillin G sodium, 10,000 μg/mL streptomycin sulfate, and
SCHEME 1. Schematic illustration of the interaction of the PDLA NPs presenting approximately 80 or 120 nm of size with ﬁbroblasts and endothelial
cells.
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25 μg/mL amphotericin B), trypLE Express and Quant-iT™
PicoGreen® dsDNA Kit were purchased to Life Technologies.
Endothelial cell growth supplement (ECGS) was purchased
from Corning. CellTiter 96 AQueous One Solution kit was
purchased from Promega, whereas the Micro BCA™ Protein
Assay Kit was purchased from TermoFisher Scientiﬁc. Dis-
tilled and ultrapure water was obtained from MiliQ-Pore.
All reagents were laboratory grade and were used as
received.
NPs preparation
NPs were produced by the nanoprecipitation method, using
two different processing conditions. The ﬁrst condition
was adapted from the literature,34–37 with some modiﬁca-
tions (Supporting Information Fig. S1), and was optimized
to obtain NPs with reproducible size distribution. Brieﬂy,
an organic solution was prepared by dissolving PDLA
(1.85 mg/mL) in acetone (5 mL), at room temperature (RT).
Then, this mixture was added dropwise onto an aqueous
solution (5 mL), under constant magnetic stirring, contain-
ing or not a hydrophilic surfactant (Pluronic® F-68) at dif-
ferent concentrations (0.10; 0.25; 0.50; 0.75; 1; 2; 3, or 5%
v/v). After stirring the solution during 5 min, the organic
solvent was removed under reduced pressure (3–8 mbar).
For drug loading and release experiments, 3 mg of predniso-
lone was added to the initial organic solution. For ﬂuores-
cence biological assays, 100 μL of ﬂuorescein isothiocyanate
(FITC) (1 mg/mL in ethanol) was added to the aqueous
solution. Non-incorporated compounds were eliminated by
centrifugation (two cycles of 45 min, 4000 rpm at 25C)
using Amicon Ultra-15 Centrifugal Filter Units. Before cen-
trifugation, glucose (1 mg/mL) was added to avoid NPs
aggregation.43
The second condition was designed to obtain NPs with a
smaller size, as adapted from the literature44 (Supporting
Information Fig. S2). Brieﬂy, an organic solution containing
the same polymer, but in different concentration
(0.37 mg/mL), was added to an aqueous solution containing
or not a surfactant. In this method, different org/aq volume
ratios (1:2, 1:3, 1:4, 1:5, 1:8, 1:10, and 1:15) were used. NPs
preparation and labeling with FITC were performed as
described above. For drug loading experiments, the protocol
was also referred above, but instead of 3 mg, 1.5 mg of pred-
nisolone was added to the PDLA solution.
Independently of the production method, all NPs suspen-
sions were kept at 4C under static conditions until further
analysis.
NPs size, PDI, and zeta potential
Size and polydispersity index (PDI) were assessed by
dynamic light scattering (DLS), and zeta potential by laser
Doppler micro-electrophoresis in a Zetasizer ZS equipment
(Malvern Instruments). The determinations were performed
at 25C using samples diluted in distilled water (1:50 v/v).
The reported values are the average of three different
measurements of, at least, three NPs populations prepared
independently (n = 3).
NPs morphology
Morphological analyzes were conducted using atomic force
microscopy (AFM; Dimension icon, BRUKER – tips Scanasyst
Air). Prior to AFM analyzes, samples were diluted to achieve
a ﬁnal concentration of 0.1 mg/mL and disposed at the
surface of a glass slide.
Long-term NPs stability
Storage stability of NPs suspensions was assessed by evalu-
ating their size, PDI and zeta potential, as well as by observ-
ing their macroscopic sedimentation. NPs were kept in water
at 4C under static conditions, during the experimental
period (6 months). At each time point, a sample dilution was
prepared and measured, as explained before.
Drug entrapment efﬁciency and loading
After the production of NPs incorporating prednisolone, the
resulting suspension was centrifuged to ensure that all
non-incorporated drug was removed, as just referred. Then,
prednisolone entrapped into NPs was quantiﬁed by high per-
formance liquid chromatography (HPLC). A Shimadzu UFLC
Prominence system equipped with two pumps LC-20 AD, an
autosampler SIL-20 AC, a column oven CTO-20 AC, a degas-
ser DGU-20A5, a system controller CBM-20A and a LC solu-
tion, version 1.24 SP1 (Shimadzu Corporation) were used. A
Shimadzu SPD-20A UV/Vis detector was coupled to the LC
system, with the wavelength set at 244 nm. A guard column
LiChrocart® LiChrospher 100 RP-18 (4 × 4 mm, 5 μm;
Merck) was connected to a Lichrocart® LiChrospher 100 RP-
18 (250 × 4.6 mm; 5 mm; Merck) column. The mobile phase
was composed by ultrapure water/acetonitrile (60:40, v/v),
at isocratic mode (1 mL/min). The injection volume of each
sample/standard was 20 μL. The speciﬁcity of the method
was conﬁrmed by comparing the chromatograms of stan-
dards with those of empty NPs.
Based on the results obtained by HPLC, drug entrapment
efﬁciency and drug loading parameters were calculated by
using the following equations:
Entrapment efficiency %ð Þ¼ Prednisolone mass inNPs
Initial prednisolone mass
×100
ð1Þ
Drug loading %ð Þ¼ Loaded prednisolone mass
TotalNPsmass
×100 ð2Þ
The mass of prednisolone in NPs suspensions was
obtained based on the peak areas of the chromatograms
(acquired in triplicate). Previously, a prednisolone calibra-
tion curve was elaborated using acetonitrile as diluent, as
for the tested samples.
In vitro drug release proﬁle
The release of prednisolone from PDLA NPs was assessed
using a dialysis cellulose tube (14.000 MWCO, Sigma-
Aldrich) as the exclusive physical barrier. The dialysis
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cellulose tubes were immersed in water for 20 min at RT
and, then, washed thoroughly with ultrapure water. After
removing the non-incorporated drug, NPs suspesions were
suspended in phosphate buffer saline (PBS) (pH = 7.4,
0.01M) and then introduced into the dialysis tubes. These
tubes containing NPs suspensions were kept in PBS at 37C,
under constant stirring. At each time point, samples of the
surrounding solution were collected to determine the
amount of prednisolone released from the NPs. An equal
quantity of fresh PBS was added to maintain the initial
releasing volume. The collected samples were diluted with
acetonitrile and analyzed by HPLC, under the previously
referred conditions.
Cell culture
Human microvascular endothelial (HPMECST1.6R) and ﬁbro-
blastic (MRC-5) cell lines, both from pulmonary origin, were
used to assess the cytocompatibility and internalization of
PDLA NPs. Endothelial cells were cultured in M199 medium
supplemented with 20% FBS, 2 mM Glutamax, 1% pen/strep
(100 U/100 μg/mL) and ECGS (50 μg/mL). MRC-5 cells were
cultured in DMEM supplemented with 10% FBS and 1%
pen/strep (100 U/100 μg/mL). Culture medium was chan-
ged twice a week and cells were split when 90% of conﬂu-
ence was reached. Cells were incubated at 37C in a
humidiﬁed 5% CO2 atmosphere. HPMECST1.6R cells were
used at passages 32–34 and MRC-5 cells at passages 13–15.
NPs cytocompatibility assay
For both selected formulations, 1:10, 1:5, and 1:2.5 dilutions
of the original suspension of PDLA NPs (0.187, 0.374, and
0.748 mg/mL, respectively) were prepared to perform bio-
logical assays. NPs suspensions were ﬁltered through
0.22 μm ﬁlters (TPP) to ensure sterility.
Cells were harvested and seeded at the bottom of
24 wells plates using 100,000 cells per well. After 24 h, cul-
ture medium was removed and wells were washed with PBS
and new culture medium containing different concentrations
of NPs was added. Cells cultured without NPs (only with cul-
ture medium) were used as controls (CTRL). After 24, 48,
and 72 h of culture, samples were collected to evaluate cell
viability (MTS), proliferation (DNA) and total protein
quantiﬁcation.
Cell viability. The metabolic activity of the cells treated or
not with different PDLA NPs concentrations was determined
by MTS assay (CellTiter 96® AQueous One Solution). Brieﬂy,
culture medium without FBS and phenol red was mixed with
MTS reagent (5:1 volume ratio) and added to each condition
(n = 3). Samples were incubated for 3 h at 37C, in a humidi-
ﬁed 5% CO2 atmosphere. The absorbance of each well
(96-well plate) was read in triplicate at 490 nm, using a
microplate reader (Synergy HT, Bio-TEK).
Cell proliferation. Cell proliferation was determined using a
ﬂuorimetric dsDNA quantiﬁcation kit (Quant-iT™
PicoGreen®; Molecular Probes). Cells were transferred to
eppendorf tubes containing 1 mL of ultrapure water and fro-
zen at −80C until further analysis. Prior to DNA quantiﬁca-
tion, cells were thawed and sonicated for 10 min. DNA
standards were prepared at concentrations ranging from
0 to 1.5 μg/mL. To each well of an opaque 96-well plate
(Falcon) were added 28.8 μL of sample or standard (n = 3),
71.2 μL of PicoGreen working solution, and 100 μL of Tris-
EDTA (TE) buffer. The plate was kept in the dark and ﬂuo-
rescence was measured in the microplate reader using an
excitation wavelength of 480 nm and an emission wave-
length of 528 nm. The dsDNA concentration of each sample
was calculated using a standard curve relating DNA concen-
tration and ﬂuorescence intensity.
Total protein quantiﬁcation. Total protein content was
quantiﬁed by micro BCA™ assay kit (Pierce Biotechnology,
ThermoFisher Scientiﬁc). The assay was performed accord-
ing to manufacturer’s instructions. Brieﬂy, standards were
prepared at various concentrations ranging from 0 to
200 μg/mL, in ultrapure water. Then, 150 μL of both sam-
ples and standards were assayed in triplicate and 150 μL of
working reagent was added to each 96-well plate. The plate
was sealed and incubated for 2 h at 37C. Afterward, the
plate was left to cool down to RT, and absorbance was read
at 562 nm in the microplate reader.
NPs internalization by endothelial and ﬁbroblastic cells.
For internalization assays, 5 × 104 HPMECST1.6R and
3 × 104 MRC-5 cells were grown on μ-slides (Ibidi) for con-
focal microscopy analysis. NPs suspensions previously pre-
pared, as explained above, were added to cultured cells.
After 1, 3, and 7 h, cells were ﬁxed with 10% formalin in
PBS and stored at 4C for further staining. Samples were
washed three times with PBS and incubated with Triton X-
100 0.2% in PBS for 5 min to permeate cell membranes. In
the following step, samples were washed with PBS and incu-
bated for 30 min with 3% bovine serum albumin (BSA) in
PBS to block non-speciﬁc protein interactions. Then, samples
were washed with PBS and incubated with phalloidin
(0.25 μg/mL) during 15 min to stain cytoskeleton, and with
DAPI (1 μg/mL) to label cell nuclei. Images of ﬂuorescent-
labeled cells and NPs were obtained by using excitation
wavelengths of 405 nm (DAPI), 488 nm (FITC labeled NPs)
and 561 nm (phalloidin). Images were acquired using a laser
scanning confocal microscopy imaging system (TCS SP8,
Leica) at 20× and 63× magniﬁcations.
Statistical analysis
Data from the NPs characterization and biological studies
was statistically analyzed using IBM SPSS software (version
21; SPSS Inc.). Shapiro–Wilk test was used to verify the
assumption of normality. p values lower than 0.01 were con-
sidered statistically signiﬁcant. Data were analyzed by a non-
parametric way by means of a Kruskal–Wallis test followed
by Turkey’s HSD test.
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RESULTS
Size distribution and zeta potential of NPs
PDLA NPs with distinct properties were obtained using
different processing conditions. First, the effect of Pluronic®
F-68 quantity over NPs size and zeta potential was evalu-
ated. As graphically represented on Figure 1(a1), the surfac-
tant has a huge inﬂuence over the size of PDLA NPs. In the
absence of Pluronic® F-68, NPs present a signiﬁcantly higher
size than in its presence. The addition of this surfactant leads
to a decrease in NPs size in a non-linear trend. In fact, the
addition of 12 times the amount of Pluronic® F-68 (0.25
comparing with 3%) leads to NPs with similar sizes. Zeta
potentials were all negative, independently of the surfactant
amount in the NPs (Fig. 1(b1)). For all formulations, the PDI
was lower than 0.1, indicating that NPs have a narrow size
distribution. Secondly, the org/aq volume ratio was varied
and its inﬂuence on the NPs properties previously consid-
ered was assessed (Fig. 1(a2, b2)). The overall results of the
org/aq volume ratio variation (using a reduced amount of
PDLA) showed that NPs size increase as the ratio increases
(Fig. 1(a2)). Independently of the org/aq ratio, the values of
zeta potentials of NPs were closer to neutrality, but still neg-
ative (Fig. 1(b2)). Finally, the presence of the Pluronic® F-68
(0.75%) in this experimental condition was also analyzed.
This surfactant led to the formation of polydisperse NPs
populations with smaller sizes (81.2  3.4 nm) and values of
zeta potential of −9.15  6.06 mV.
Based on the previous observations, the conditions
0.25% Pluronic® F-68 and 1:3 org/aq volume ratio without
surfactant were selected for further studies and, from now
on, designated as types A (120 nm) and B (80 nm) NPs,
respectively.
NPs morphology
NPs morphology was evaluated by AFM. The micrographs
showed that both types of NPs present a spherical morphol-
ogy (Fig. 2). Figure 2(a) showed larger NPs than Figure 2(b),
corroborating the size measurements assessed by DLS for
FIGURE 1. Size (A) and zeta-potential (B) of PDLA NPs produced with different percentages of Pluronic® F-68 (1) or org/aq volume ratios (2). Results
represent median (Q2), Q1 and Q3 values. Statistical analysis was performed and data were considered signiﬁcantly different if p < 0.01; (1)
a denotes signiﬁcant differences compared to 0%, b denotes signiﬁcant differences compared to 0.10%, c denotes signiﬁcant differences compared
to 0.50% and d denotes signiﬁcant differences compared to 0.75%; (2) a denotes signiﬁcant differences compared to 1:3, b denotes signiﬁcant
differences compared to 1:2, c denotes signiﬁcant differences compared to 1:4, d denotes signiﬁcant differences compared to 1:5 and e denotes
signiﬁcant differences compared to 1:8.
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types A and B NPs, respectively. A similar conclusion was
obtained for NPs size distribution, once it is possible to visu-
alize a more heterogeneous population in Figure 2(b) rather
than in Figure 2(a).
Long-term stability
The stability study allowed ensuring the period of time that
NPs can be used without an appreciable change of their size,
avoiding the occurrence of aggregation and sedimentation in
the suspension. Both populations of NPs were kept in water
at 4C, under static conditions. In Figure 3(a) it can be
observed that type A NPs kept their size constant during the
entire period of time. On the other hand, type B NPs
increased their size just 2 weeks after the beginning of the
experiment. PDI values of type A NPs kept below 0.1 and for
type B NPs they were above 0.2 without a signiﬁcant change
along the time (data not shown). Regarding zeta potential,
both NPs populations presented oscillations in the values of
this parameter over time (Fig. 3(b)). Sedimentation analysis
allowed observing that type B NPs suspensions have a ten-
dency to precipitate over time, contrarily to what was
observed for type A NPs.
Drug loading, entrapment efﬁciency and in vitro drug
release proﬁle from NPs
Table I presents the results obtained for prednisolone
entrapment and loading in type A and type B NPs. It can be
observed that type A NPs presented higher values of entrap-
ment efﬁciency and drug loading than type B NPs.
After quantifying the amount of encapsulated predniso-
lone, it was evaluated its in vitro release proﬁle (Fig. 4). For
both types of NPs, the release of prednisolone presented two
different phases: ﬁrst, a burst release and, then, a slight
increase in the amount of prednisolone released. It was also
possible to observe that type A and type B NPs released
90% of entrapped drug after 24 h and 5 h of the study
beginning, respectively.
Biological assays
Human endothelial cells (HPMECST1.6R cell line) were used
as a model of vascular endothelium to study NPs uptake. It
was also evaluated the ability of NPs to enter in human
ﬁbroblastic cells (MRC-5 cell line), since ﬁbroblasts are the
most common cells of connective tissues and have an impor-
tant role in wound healing. Therefore, their cytocompatibility
and internalization were assessed to allow concluding
about the feasibility of using them in these two biological
environments.
NPs cytocompatibility assay. Cell viability (assessed by MTS
assay), cell proliferation (assessed by dsDNA quantiﬁcation;
PicoGreen assay) and total protein content (microBCA assay)
were determined for human endothelial (Fig. 5) and ﬁbro-
blastic cells (Fig. 6), cultured during 24, 48, and 72 h with
type A or type B NPs.
No substantial differences were observed, in terms of met-
abolic activity, for both cell types at any time point, and for
both types of NPs. Nevertheless, some statistically signiﬁcant
FIGURE 2. AFM microphotographs of the selected PDLA NPs: type A (a) and type B (b) populations.
FIGURE 3. Size (A) and zeta potential (B) of type A (black circles) and type B (gray squares) NPs stored at 4C in water. Data represent
mean  SD (n = 3).
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differences were observed: endothelial cells exposed to NPs
suspensions at a concentration of 0.748 mg/mL showed mini-
mal toxicity, especially after 48 h of culture (Fig. 5(a,d)). In
terms of dsDNA quantiﬁcation, for both cell types cultured
with both types of NPs, it was possible to observe no statisti-
cally signiﬁcant differences throughout the experiment. Rela-
tively to total protein content, no statistically signiﬁcant
differences were observed for both types of NPs and for both
cell types along time. Though, for ﬁbroblastic cells exposed to
type A NPs at a concentration of 0.748 mg/mL after 48 h and
72 h, a lower protein concentration was obtained, when com-
pared with the other conditions (Fig. 6(c, f )). Similar results
were observed for endothelial cells cultured with type A NPs
(Figs. 5(c)).
Nanopartiles internalization. For cells internalization assay,
both cell types were exposed during 1, 3, and 7 h to both
types of NPs. Their subcellular localization can be observed
in Figures 7 and 8. Confocal images showed that ﬁbroblastic
cells did not internalize any type of NPs, independently of
the time of exposure (Figs. 7(b) and 8(d)). By comparing the
micrographs shown in Figure 7(a, c), it is possible to observe
that endothelial cells internalized only type A NPs after
3 and 7 h of incubation (Fig. 8). Moreover, cells morphology
did not appear to be affected by the presence of NPs (Fig. 7).
DISCUSSION
Herein, the inﬂuence of surfactant concentration
(i.e., Pluronic® F-68) and the org/aq volume ratio over NPs
physical properties was studied. In a further step, and envi-
sioning the use of such NPs in therapeutic applications, an
anti-inﬂammatory drug (i.e., prednisolone) was loaded into
the polymeric NPs structure. Both entrapment and loading
efﬁciencies, as well as drug release proﬁle, were evaluated.
Considering the future clinical application of NPs, cellular
studies (viability, dsDNA, and total protein quantiﬁcation, as
well as cell internalization) were conducted.
Several works in the literature claim that poloxamers (com-
mercially known as Pluronic®) prevent aggregation of NPs.45
Furthermore, Pluronic® F-68 has the ability to enhance the drug
release proﬁle, NPs stability and cell interactions.46,47 This sur-
factant can also inﬂuence the kinetics of particles clearance. For
example, MPs that are usually found in the liver, when coated
TABLE I. Entrapment efﬁciency and loading of prednisolone in
type A and type B NPs
NPs type Entrapment efﬁciency (%) Drug loading (%)
A 9.69  3.14 32.56  2.76
B 6.13  1.43 14.12  0.86
FIGURE 4. Prednisolone release proﬁle from type A (a) and type B (b) NPs at 37C. The inset show the release proﬁle over the ﬁrst 5 h. Data repre-
sent mean  SD (n = 3).
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with Pluronic® F-68 or Pluronic® F-108 were found in lungs.48
In fact, coated particles are less covered by opsonins, prevent-
ing phagocytic engulfment.48 Therefore, Pluronic® F-68 was
included in the PDLA NPs fabrication method. Experimental
data did not allow establishing a linear correlation between the
concentration of Pluronic® F-68, NPs size and zeta potential,
which might be explained by the presence of different types of
interactions between the compounds present in solution. How-
ever, we observed that NPs size is signiﬁcantly smaller for the
ones prepared with Pluronic® F-68, but higher amounts of this
surfactant did not result in a similar trend in the reduction of
NPs size. Indeed, NPs with similar sizes were obtained even
after the addition of 12 times the amount of Pluronic® F-68
(0.25 comparing with 3%). In a second approach, different
experimental conditions, namely the org/aq volume ratio, were
implemented to obtain smaller NPs (inferior to 100 nm). The
org/aq volume ratios variation led to NPs whose size values
increase as the ratio increases. For all analyzed ratios, the 1:3
ratio was the one that produced smaller NPs.
Two types of NPs with statistically different average
sizes (120 nm – type A; 80 nm – type B) were selected. Stor-
age stability assays showed that type A NPs conserved their
size during, at least, 6 months at 4C. At this temperature it
is favored the stability of the NPs suspension for longer
periods of time. Indeed, it has been described in the litera-
ture that lower temperatures of storage ensures a higher
chemical stability of the polymers and minimize NPs
aggregation.49,50
The possibility of NPs aggregation was analyzed by zeta
potential, size and PDI determinations over time. Through
the analysis of these parameters, it can be concluded that
type A NPs did not aggregate or considerably degrade. In
accordance, macroscopic sedimentation evaluation did not
show the appearance of a precipitate or other visible alter-
ation in the NPs suspension. These results ensure that the
NPs can be used without an appreciable change of their
characteristics after preparation in the period of time consid-
ered. On the other hand, the stability of type B NPs showed
to be signiﬁcantly lower as they rapidly increase in size after
the 15th day of storage, keeping constant their polydisper-
sity. This fact is corroborated by Ming et al.44 that reported
an increase of 50 nm on PLGA NPs size after 2 weeks of
their preparation. The increase of type B NPs size with time
can be due to their smaller zeta potential values (ranging
from 0 to −10 mV) and, as a consequence, no strong repul-
sive forces are present. The instability was also conﬁrmed
by the macroscopic sedimentation analysis in which NPs
aggregates are present in a higher amount.
The assessment of prednisolone entrapment efﬁciency
and loading, as well as it is in vitro release proﬁle, demon-
strated that PDLA NPs can be a good carrier for this drug.
Although the values of entrapment efﬁciency and loading are
FIGURE 5. Human endothelial cells behavior after exposure to type A NPs suspensions (cells viability [A], dsDNA concentration [B] and total protein
content [C]) and to type B NPs suspensions (cells viability [D], dsDNA concentration [E], and total protein content [F]) at different concentrations
(0.187 – dotted squares, 0.374 – oblique lines in squares, 0.748 mg/mL – parallel lines in squares, and CTRL – white squares) for each time point
(24 h, 48 h, and 72 h). CTRL refers to endothelial cells cultured without NPs. Statistical analysis was performed for all the conditions comparing each
concentration for each time point. Data were considered statistically different for p < 0.01. + denotes signiﬁcant differences compared to CTRL,
* denotes signiﬁcant differences compared to concentration 0.748 mg/mL.
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low, it was demonstrated that higher entrapment efﬁciencies
did not imply more entrapped drugs.51 Indeed, having into
consideration the plasma concentration of prednisolone after
oral administration,52 the plasma volume53 and the mass of
the drug incorporated per batch of produced NPs (for exam-
ple, 177  26 mg for type A NPs), it can be anticipated that
the synthetic glucocorticoid is present in an adequate
amount to counteract an inﬂammatory process. Additionally,
as prednisolone is incorporated into NPs, it is expected that
the plasma concentration will be lower than the obtained
with an oral formulation, but higher at the desired local of
action.
Prednisolone mode of action is based on its high binding
afﬁnity to glucocorticoid receptors that reside in the cyto-
sol.54 Since this cascade is dependent on the delivery of
prednisolone inside the cells to form the steroid/receptor
complex, NPs internalization by cells is of major importance.
Our experimental data demonstrated that larger NPs (type A
NPs) were internalized while smaller (type B NPs) were not,
under the experimental conditions used in this work. In fact,
while some authors report that the internalization of smaller
NPs is higher when comparing to larger NPs,55,56 others
state that there is an ideal NP size for cell internalization to
occur.57,58 Speciﬁcally, in the work developed by Win and
Feng58, PLGA NPs with 100 nm were 2.3-fold more internal-
ized than with 50 nm. Despite herein was used PDLA instead
of PLGA, our ﬁndings are similar to those of Win and Feng.58
The biological assays were performed with cell lines pre-
senting a human pulmonary origin but different phenotypes:
endothelial (HPMECST1.6R cell line) and ﬁbroblastic (MRC-5
cell line) cells. Fibroblastic cells did not internalize any type
of NPs and endothelial cells only internalize 120 nm NPs
within our testing conditions. Indeed, there are critical
parameters that can inﬂuence the internalization of the NPs
by cells, such as the size, shape and surface chemistry of the
NPs, as well as the target cell.59 Therefore, among these criti-
cal factors, probably the size of the developed NPs is not the
ideal to be internalized by human ﬁbroblasts. Indeed, a study
performed to evaluate the inﬂuence of single-walled carbon
nanotubes size in their uptake by ﬁbroblasts also demon-
strated that there is a favored size that allows their highest
uptake.60
The endothelial uptake of circulating NPs is not only fun-
damental to obtain a localized therapeutic effect, but also to
achieve an effective targeting of the NPs in different tissues.
The endothelial barrier is composed of a monolayer of endo-
thelial cells with 1 nm tight junctions and 3 nm adherents
junctions.61 Thus, those intercellular spaces are too small for
FIGURE 6. Human ﬁbroblastic cells behavior after exposure to type A NPs suspensions (cells viability [A], dsDNA concentration [B] and total protein
content [C]) and to type B NPs suspensions (cells viability [D], dsDNA concentration [E], and total protein content [F]) at different concentrations
(0.187, 0.374, 0.748 mg/mL and CTRL) for each time point (24 h [white squares], 48 h [dotted squares], and 72 h [striped squares]). CTRL refers to
ﬁbroblastic cells cultured without NPs. Statistical analysis was performed for all conditions comparing each concentration for each time point. Data
was considered statistically different for p < 0.01. + denotes signiﬁcant differences compared to CTRL, *denotes signiﬁcant differences compared to
concentration 0.748 mg/mL and x denotes signiﬁcant differences compared to concentration 0.374 mg/mL.
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enabling the extravasation of the NPs. Then, for the NPs to
get into the basal side, they should ﬁnd other alternative
paths. The transcellular caveolar pathway, present in endo-
thelial cells of various organs, could provide an alternative
intracellular pathway to pass this barrier. Caveolae have
70 nm in diameter, thus smaller NPs may be preferentially
transported by this mechanism than larger NPs.62,63 How-
ever, our experimental results show that only 120 nm NPs
FIGURE 7. Confocal microscopy images of endothelial (A, C) and ﬁbroblastic (B, D) cells cultured during 3 h with 0.748 mg/mL type A (A, B) and type
B (C, D) NPs. Cytoskeleton is labeled with phalloidin (in red), nuclei with DAPI (in blue) and NPs, with FITC (in green). Small images show the green
channel for a better observation of FITC-NP distribution inside the cellular monolayer.
FIGURE 8. Confocal microscopy images of endothelial cells cultured with 0.748 mg/mL type A NPs (in green, FITC), after 1 (A) 3 (B), and 7 h (C),
being the nuclei in blue (DAPI) and the cytoskeleton in red (phalloidin). The green channel is shown for a better observation of FITC-NP distribution
inside the cellular monolayer.
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were internalized by human endothelial cells. This result
indicates that their intracellular pathway is being used. Con-
sequently, further work is necessary to understand the
mechanism regulating the internalization and intracellular
pathway of the NPs in the endothelial cells.
CONCLUSIONS
The present study enables concluding that, by adjusting one
or more processing parameters of the nanoprecipitation
method, it is possible to obtain two statistically different
sizes/populations of NPs (i.e., 120 and 80 nm). Their perfor-
mance as drug delivery systems was validated with the
incorporation and sustained release of prednisolone. The
developed NPs are cytocompatible as shown in cultures of
human endothelial and ﬁbroblastic cells. Furthermore, the
two NPs populations presented different internalization pro-
ﬁle, depending on NPs size: the endothelial cell line can
internalize NPs with 120 nm, whereas ﬁbroblasts did not
evidenced internalization of the NPs, independently of their
size. The differential internalization proﬁle will be further
analyzed in a more in depth study to quantify the internali-
zation of the NPs as well as to study their internalization
mechanism by the cells.
In summary, it is possible to conclude that the produc-
tion of PDLA NPs was successfully optimized to obtain drug
delivery devices with promising performance for the treat-
ment of inﬂammatory diseases.
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